|
1
|
American Society of Hematology (ASH): Blood cancers. ASH, Washington, DC, 2020. http://www.hematology.org/Patients/Cancers/. Accessed October 10, 2020.
|
|
2
|
Paraguassu-Chaves CA, Filho AKDB, Almeida F, Dantas LRM, Neto JVF, dos Santos AM and Simões MDCR: Epidemiological, Sociodemographic And Clinical Profile of Men With Cancer in Rondônia, Brazilian Amazon. Int J Innov Educ Res. 8:374–408. 2020.
|
|
3
|
Apperley JF: Chronic myeloid leukaemia. Lancet. 385:1447–1459. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E and Cairo MS: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 97:2998–3003. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bitencourt R, Zalcberg I and Louro ID: Imatinib resistance: A review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 33:470–475. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 367:2075–2088. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Merkulova A, Mitchell SC, Stavrou EX, Forbes GL and Schmaier AH: Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. Blood Adv. 3:2312–2316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Westerweel PE, te Boekhorst PAW, Levin MD and Cornelissen JJ: New approaches and treatment combinations for the management of chronic myeloid Leukemia. Front Oncol. 9(665)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE and van der Kuip H: Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res. 69:9337–9345. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xiao LY and Kan WM: p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells. Pharmacol Res. 119:443–462. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
No authors listed. Lobaplatin: D 19466. Drugs R D. 4:369–372. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dasari S and Tchounwoun PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kilari D, Guancial E and Kim ES: Role of copper transporters in platinum resistance. World J Clin Oncol. 7:106–113. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rampello E, Fricia T and Malaguarnera M: The management of tumor lysis syndrome. Nat Clin Pract Oncol. 3:438–447. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Belay Y, Yirdaw K and Enawgaw B: Tumor lysis syndrome in patients with hematological malignancies. J Oncol. 2017(9684909)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Howard SC, Jones DP and Pui CH: The tumor lysis syndrome. N Engl J Med. 364:1844–1854. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alakel N, Middeke JM, Schetelig J and Bornhäuser M: Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther. 10:597–605. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW and Alan Andersen F: Final report of the safety assessment of allantoin and its related complexes. Int J Toxicol. 29 (Suppl 3):84S–97S. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Araujo LU, Reis PG, Barbosa LC, Saude-Guimaraes DA, Grabe-Guimaraes A, Mosqueira VC, Carneiro CM and Silva-Barcellos NM: In vivo wound healing effects of Symphytum officinale L. leaves extract in different topical formulations. Pharmazie. 67:355–360. 2012.PubMed/NCBI
|
|
21
|
Kandar R, Stramova X, Drabkova P and Krenkova J: A monitoring of allantoin, uric acid, and malondialdehyde levels in plasma and erythrocytes after ten minutes of running activity. Physiol Res. 63:753–762. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fernandes J, de Amorim GC, da Veiga TE, Cardoso J, Arruda AC, Arruda MSP and Castelo-Branco MTL: Allantoin reduces cell death induced by cisplatin: Possible implications for tumor lysis syndrome management. J Biol Inorg Chem. 24:547–562. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xiao LY and Kan WM: p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells. Pharmacol Res. 119:443–462. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xiao LY and Kan WM: Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells. Anticancer Drugs. 28:316–321. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Daugan M, Dufay Wojcicki A, d'Hayer B and Boudy V: Metformin: An anti-diabetic drug to fight cancer. Pharmacol Res. 113 (Pt A):675–685. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liang X and Giacomini KM: Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci. 106:2245–2250. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Pernicova I and Korbonits M: Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 10:143–156. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, Moon JW, Kim JH, Kim SJ, Lee EJ, et al: Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res. 21(115)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Guo L, Cui J, Wang H, Medina R, Zhang S, Zhang X, Zhuang Z and Lin Y: Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways. Mol Ther Oncolytics. 20:119–131. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yu H, Bian X, Gu D and He X: Metformin synergistically enhances cisplatin-induced cytotoxicity in esophageal squamous cancer cells under glucose-deprivation conditions. Biomed Res Int. 2016(8678634)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ma M, Ma C, Li P, Ma C, Ping F, Li W, Xu L, Zhang H, Sun Q and Li Y: Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p. Cell Cycle. 19:2168–2181. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Surin AM, Sharipov RR, Krasil'nikova IA, Boyarkin DP, Lisina OY, Gorbacheva LR, Avetisyan AV and Pinelis VG: Disruption of functional activity of mitochondria during MTT assay of viability of cultured neurons. Biochemistry (Mosc). 82:737–749. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lalle M, Camerini S, Cecchetti S, Finelli R, Sferra G, Müller J, Ricci G and Pozio E: The FAD-dependent glycerol-3-phosphate dehydrogenase of Giardia duodenalis: An unconventional enzyme that interacts with the g14-3-3 and it is a target of the antitumoral compound NDBHEX. Front Microbiol. 6(544)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Vial G, Detaille D and Guigas B: Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne). 10(294)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
MacDonald MJ, Ansari IH, Longacre MJ and Stoker SW: If Metformin Inhibited the Mitochondrial Glycerol Phosphate Dehydrogenase It Might Not Benefit Diabetes. bioRxiv: doi: https://doi.org/10.1101/2020.03.28.013334.
|
|
36
|
El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 275:223–228. 2000.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ, Han X, Wang HY, Sun GP and Liu H: Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 11:1700–1706. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lomeli N, Di K, Czerniawski J, Guzowski JF and Bota DA: Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 102:274–286. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Choi YM, Kim HK, Shim W, Anwar MA, Kwon JW, Kwon HK, Kim HJ, Jeong H, Kim HM, Hwang D, et al: Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One. 10(e0135083)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Teixeira SF, Guimarães Idos S, Madeira KP, Daltoé RD, Silva IV and Rangel LB: Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells. J Bras Pneumol. 39:644–649. 2013.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
|
|
41
|
Bi T, Zhu A, Yang X, Qiao H, Tang J, Liu Y and Lv R: Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. Cytotechnology. 70:439–448. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Berridge MV and Tan AS: Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 303:474–482. 1993.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et al: Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang S, Xie J, Li J, Liu F, Wu X and Wang Z: Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin β5-mediated glycolysis. Am J Cancer Res. 6:1108–1117. 2016.PubMed/NCBI
|
|
45
|
Skinner AL and Laurence JS: High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands. J Pharm Sci. 97:4670–4695. 2008.PubMed/NCBI View Article : Google Scholar
|
